Eplerenone Attenuates Pulse Wave Reflection in Chronic Kidney Disease Stage 3-4 - A Randomized Controlled Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Boesby, Lene ^a   Elung Jensen, Thomas ^a   Strandgaard, Svend ^a   Kamper, Anne Lise ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY PULSE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; FEMORAL ARTERY; GLOMERULONEPHRITIS; GOUT; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PULSE WAVE; RADIATION ATTENUATION; RANDOMIZED CONTROLLED TRIAL; TONGUE SWELLING; TREATMENT RESPONSE; URINARY EXCRETION;

BLOOD PRESSURE; DEMOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; VASCULAR STIFFNESS;

EID: 84877969830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064549     Document Type: Article

References (33)

1. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, et al. (2001) Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59 (5) (): 1834-1841.
2. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, et al. (2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103 (7) (): 987-992.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, et al. (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (18) (): 2434-2439.
4. Li Y, Dolan E, Wang JG, Thijs L, Zhu DL, et al. (2006) Ambulatory arterial stiffness index: determinants and outcome. Blood Press Monit 11 (2) (): 107-110.
5. Hansen TW, Li Y, Staessen JA, Jeppesen J, Rasmussen S, et al. (2008) Independent prognostic value of the ambulatory arterial stiffness index and aortic pulse wave velocity in a general population. J Hum Hypertens 22 (3) (): 214-216.
6. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, et al. (2006) Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113 (5) (): 664-670.
7. Blacher J, Safar ME, Pannier B, Guerin AP, Marchais SJ, et al. (2002) Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens 11 (6) (): 629-634.
8. Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E, (2011) The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. J Hum Hypertens 26 (8) (): 476-84.
9. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, et al. (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (5) (): 1236-1241.
10. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, et al. (2001) Arterial wave reflections and survival in end-stage renal failure. Hypertension 38 (3) (): 434-438.
11. Asmar RG, London GM, O'Rourke ME, Safar ME, (2001) for the REASON Project coordinators and investigators (2001) Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections With a Very-Low-Dose Perindopril/Indapamide Combination in Hypertensive Patient. Hypertension 38 (4) (): 922-926.
12. Frimodt-Moller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH, (2012) Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease-a randomized trial. PLoS One 7 (7) (): e41757.
13. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, et al. (2011) Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 29 (6) (): 1034-1042.
14. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (9) (): 1213-1225.
15. Booth RE, Johnson JP, Stockand JD, (2002) Aldosterone. Adv Physiol Educ 26 (1-4) (): 8-20.
16. Brown NJ, (2008) Aldosterone and vascular inflammation. Hypertension 51 (2) (): 161-167.
17. Hene RJ, Boer P, Koomans HA, Mees EJ, (1982) Plasma aldosterone concentrations in chronic renal disease. Kidney Int 21 (1) (): 98-101.
18. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, et al. (2006) Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 7 (1) (): 31-39.
19. Savoia C, Touyz RM, Amiri F, Schiffrin EL, (2008) Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51 (2) (): 432-439.
20. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (5) (): 1021-1026.
21. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN, (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54 (6) (): 505-512.
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (9) (): 604-612.
23. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S, (2006) Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions. Scand J Clin Lab Invest 66 (5) (): 385-394.
24. Vickers AJ, Altman DG, (2001) Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 323 (7321) (): 1123-1124.
25. Weber T, Ammer M, Gunduz D, Bruckenberger P, Eber B, et al. (2011) Association of Increased Arterial Wave Reflections With Decline in Renal Function in Chronic Kidney Disease Stages 3 and 4. Am J Hypertens 24 (7) (): 762-769.
26. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S, (2008) Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 23 (2) (): 594-600.
27. Borresen ML, Wang D, Strandgaard S, (2007) Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 27 (3) (): 240-246.
28. Boesby L, Thijs L, Elung-Jensen T, Strandgaard S, Kamper AL, (2012) Ambulatory arterial stiffness index in chronic kidney disease stage 2-5. Reproducibility and relationship with pulse wave parameters and kidney function. Scand J Clin Lab Invest pp. 1-9.
29. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension (2003) J Hypertens 21 (6) (): 1011-1053.
30. Elung-Jensen T, Strandgaard S, Kamper AL, (2008) Longitudinal observations on circadian blood pressure variation in chronic kidney disease stages 3-5. Nephrol Dial Transplant 23 (9) (): 2873-2878.
31. Briet M, Schiffrin EL, (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6 (5) (): 261-273.
32. Bomback AS, Klemmer PJ, (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3 (9) (): 486-492.
33. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL, (2011) Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 6 (11) (): e26904.